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Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable 127 
basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European 128 
ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the 129 
new and previously-reported European CRC loci, and a further nine CRC SNPs at loci previously only 130 
identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico 131 
annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations 132 
implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight 133 
novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into 134 
CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and 135 
prevention. 136 
 137 
  138 
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INTRODUCTION 139 
Many colorectal cancers (CRC) develop in genetically susceptible individuals1 and genome-wide association 140 
studies (GWAS) of CRC have thus far reported 43 SNPs mapping to 40 risk loci in European populations2,3. In 141 
Asians, 18 SNPs mapping to 16 risk loci have been identified4,5, a number of which overlap with those 142 
reported in Europeans. Collectively across ethnicities GWAS has provided evidence for 53 unique CRC 143 
susceptibility loci. While much of the heritable risk of CRC remains unexplained, statistical modelling indicates 144 
that further common risk variants remain to be discovered6.  145 
 146 
To gain a more comprehensive insight into CRC aetiology, we conducted a GWAS meta-analysis that includes 147 
additional, unreported data sets. We examine the possible gene regulatory mechanisms underlying all GWAS 148 
risk loci by analysing in situ promoter Capture Hi-C (CHi-C) to characterise chromatin interactions between 149 
predisposition loci and target genes, examine gene expression data, and integrate these data with chromatin 150 
immunoprecipitation-sequencing (ChIP-seq) data. Finally, we quantify the contribution of new and previously 151 
discovered loci to the heritable risk of CRC and estimate the sample sizes required to explain the remaining 152 
heritability. 153 
 154 
RESULTS 155 
Association analysis 156 
Thus far, studies have identified 61 SNPs that are associated with CRC risk in European and Asian populations 157 
(Supplementary Data 1). To identify additional CRC risk loci, we conducted five new CRC GWAS, followed by a 158 
meta-analysis with 10 published GWAS totalling 34,627 cases and 71,379 controls of European ancestry under 159 
the auspices of the COGENT (COlorectal cancer GENeTics) consortium7 (Fig.1, Supplementary Data 2). 160 
Following established quality control measures for each dataset8 (Supplementary Data 3), the genotypes of 161 
over 10 million SNPs in each study were imputed, primarily using 1000 Genomes and UK10K data as reference 162 
(see Methods). After filtering out SNPs with a minor allele frequency of <0.5% and imputation quality score 163 
<0.8, we assessed associations between CRC status and SNP genotype in each study using logistic regression. 164 
Risk estimates were combined through an inverse variance weighted fixed-effects meta-analysis. We found 165 
little evidence of genomic inflation in any of the GWAS datasets (individual λGC values 1.01-1.11; meta-analysis 166 
λ1000 = 1.01, Supplementary Figure 1).  167 
 168 
Excluding flanking regions of 500kb around each previously identified CRC risk SNP, we identified 623 SNPs 169 
associated with CRC at genome-wide significance (logistic regression, P < 5 x 10-8). After implementing a 170 
stepwise model selection, these SNPs were resolved into 31 novel risk loci, with 27 exhibiting Bayesian False 171 
Discovery Probabilities (BFDPs)9 < 0.1 (Table 1, Fig.2, Supplementary Figure 2). The association at 20q13.13 172 
(rs6066825) had only been previously identified as significant in a multi-ethnic study10. Two new associations 173 
(rs3131043 and rs9271770) were identified within the 6p21.33 major histocompatibility (MHC) region, with 174 
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rs3131043 located 470kb 5’ of HLA-C, and rs9271770 located between HLA-DRB1 and HLA-DQA1. Imputation 175 
of the MHC region using SNP2HLA11 provided no evidence for additional MHC risk loci.  176 
 177 
We confirmed 28 of the 40 risk loci for CRC published as genome-wide significant in Europeans (i.e. P < 5 x 10-178 
8) (Supplementary Data 1). For four previously reported risk loci2,12-14, we observed associations that were just 179 
below genome-wide significance (3q26.2, rs10936599, P = 1.41 x 10-7; 12p13.32, rs3217810, P = 1.09 x 10-6; 180 
16q22.1, rs9929218, P = 4.96 x 10-7; 16q24.1, rs2696839, 1.28 x 10-6). In contrast, there was limited support in 181 
our current study for eight of the associations previously reported by others2,10,15-17 (2q32.3, rs11903757, P = 182 
0.23; 3p14.1, rs812481, P = 0.44; 4q22.2, rs1370821, P = 3.41 x 10-5; 4q26, rs3987, P = 0.10; 4q32.2, 183 
rs35509282, P = 0.24; 10q11.23, rs10994860, P = 3.65 x 10-4; 12q24.22, rs73208120, P = 0.03; 20q11.22, 184 
rs2295444, P = 0.03), all having a BFDP > 0.99 (Supplementary Data 1). Of the 16 reported Asian-specific 185 
loci4,5, nine harboured genome-wide significant signals in the current study (all BFDP < 0.06), albeit sometimes 186 
at SNPs with low r2 but high D’ with the original SNP in Europeans, consistent with differences in allele 187 
frequencies in the different populations (Supplementary Data 1). Conditioning on the reported Asian SNPs, 188 
five of the nine European risk SNPs were independent of the Asian SNP (Pconditional < 5 x 10-8, Supplementary 189 
Data 4). We found no evidence of association signals at the remaining previously reported Asian SNPs.  190 
 191 
Next, we performed an analysis conditioned on the sentinel SNP (r2 < 0.1 and Pconditional < 5 x 10-8; Table 2) to 192 
search for further independent signals at these new and previously reported risk loci. We confirmed the 193 
presence of previously reported dual signals at 14q22.2, 15q13.3 and 20p12.318. For the new risk loci, an 194 
additional independent signal was identified at 5p15.3. In addition, a further seven signals were found at five 195 
previously-reported risk loci: 11q13.4, 12p13.32, 15q13.3, 16q24.1, 20q13.13. Two of these signals were at 196 
the 15q13.3 locus, of which one was 5’ of GREM1 and the other intronic to FMN1. A further two signals were 197 
proximal and distal of 20q13.13. At 12p13.32 and 16q24.1, genome-wide associations marked by rs12818766 198 
and rs899244 respectively were shown. These were independent of the previously reported associations2,14 at 199 
rs3217810 and rs2696839 (pairwise r2 = 0.0).  200 
 201 
In total, we identified 39 new independent SNPs associated with CRC susceptibility at genome-wide 202 
significance in Europeans. Together with the nine associations previously identified in Asian populations, and 203 
the 31 previously identified SNPs that were confirmed here, this brought the number of identified CRC 204 
association signals in Europeans to 79. Several of these risk loci map to regions previously identified in other 205 
cancers. In particular, three regions harbour susceptibility loci for multiple cancers19, specifically 5p15.33 206 
(TERT-CLPTM1L), 9p21.3 (CDKN2A) and 20q13.33 (RTEL1) (Supplementary Data 5). 207 
 208 
Functional annotation and biological inference of risk loci 209 
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To the extent that they have been deciphered, most GWAS risk loci map to non-coding regions of the genome 210 
influencing gene regulation19. Consistent with this, we found evidence that the CRC risk SNPs mapped to 211 
regions enriched for active enhancer marks (H3K4me1 and H3K27ac) in colonic crypts (permutation test, P = 212 
0.034 and 0.033, respectively) and colorectal tumours (P = 4.2 x 10-3 and 4.0 x 10-5) (Supplementary Figure 3). 213 
To determine whether the CRC SNPs overlapped with active regulatory regions in a cell-type specific 214 
manner20, we analysed the H3K4me3, H3K27ac, H3K4me1, H3K27me3, H3K9ac, H3K9me3, and H3K36me3 215 
chromatin marks across multiple cell types from the NIH Roadmap Epigenomics project21. Colonic and rectal 216 
mucosa cells showed the strongest enrichment of risk SNPs at active enhancer and promoter regions 217 
(H3K4me3, H3K4me1, H3K27ac marks, P < 5 x 10-4) (Supplementary Figure 3).  218 
 219 
Given our observation that the risk loci map to putative regulatory regions, we examined both histone 220 
modifications and transcription factor (TF) binding sites in LoVo and HT29 CRC cells across the risk SNPs. Using 221 
variant set enrichment22, we identified regions of strong LD (defined as r2 > 0.8 and D′ > 0.8) with each risk 222 
SNP and determined the overlap with ChIP-seq data from the Systems Biology of Colorectal cancer (SYSCOL) 223 
study and in house-generated histone data. We identified an over-representation of binding for MYC, ETS2, 224 
cohesin loading factor NIPBL, and cohesin-related proteins RAD21, SMC1A, and SMC3 (Supplementary Figure 225 
4). 87% (69/79) of the risk SNPs were predicted to disrupt binding motifs of specific TFs, notably CTCF, SOX, 226 
and FOX, with 35% located within TF binding peaks from LoVo, HT29, or ENCODE ChIP-seq data 227 
(Supplementary Data 6). 228 
 229 
The upstream mechanisms by which predisposition SNPs influence disease risk is often through effects on cis-230 
regulatory transcriptional networks, specifically through chromatin looping interactions that are fundamental 231 
for regulation of gene expression. Therefore, to link regulatory regions containing risk SNPs to promoters of 232 
candidate target genes, we applied in situ promoter capture Hi-C (CHi-C) data in LoVo and HT29 cells (Table 233 
3). 38% of the risk SNPs mapped to regions that showed statistically significant chromatin-looping interactions 234 
with the promoters of respective target genes. Notably, as well as confirming the interaction between 235 
rs6983267 and MYC at 8q24.21 (Supplementary Figure 2), the looping interaction from an active enhancer 236 
region at 10q25.2 implicates TCF7L2 as the target gene of rs12255141 variation (Fig.3). TCF7L2 (previously 237 
known as TCF4) is a key transcription factor in the Wnt pathway and plays an important role in the 238 
development and progression of CRC23. Intriguingly, TCF7L2 has been shown to bind to a MYC enhancer 239 
containing rs698326724 and to a GREM1 enhancer near rs1696968125. Based on ChromHMM, this region is 240 
annotated as a promoter in HCT116 cells, but not in normal colonic and rectal mucosa. Additionally this locus 241 
has been implicated in lung cancer26 and low-grade glioma27. Similarly, the 9p21.3 chromatin interaction 242 
provides evidence to support CDKN2B as the target gene for rs1412834 variation, a region of somatic loss. 243 
 244 
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We sought to gain further insight into the target genes at each locus, and hence the biological mechanisms for 245 
the associations, by performing expression quantitative trait locus (eQTL) analysis in colorectal tissue. We 246 
analysed in-house eQTL data generated from samples of normal colonic mucosa (INTERMPHEN study, n = 131 247 
patients) and GTEx data from transverse colon (n = 246). For the previously identified risk loci, there were 248 
eQTLs for rs4546885 and LAMC1 (1q25.3), rs13020391 and lnc-RNA RP11-378A13.1 (2q35), and rs3087967 249 
and COLCA1, COLCA2 and C11orf53 (11q23.1). Amongst the eQTL associations at the new risk loci, pre-250 
eminent eQTLs were rs9831861 and SFMBT1 (3p21.1), rs12427600 and SMAD9 (13q13.3), and rs12979278 251 
and FUT2 and MAMSTR (19q13.33) (Supplementary Data 7). However, while multiple nominally significant 252 
cis-eQTLs were present, nearly half of all loci had no evidence of cis-eQTLs in the sample sets used. 253 
In addition to eQTL analysis, we performed Summary-data-based Mendelian Randomization (SMR) analysis28 254 
as a more stringent test for causal differences in gene transcription (Supplementary Data 8). There was 255 
support for the 11q23.1 locus SNP influencing CRC risk through differential expression of one or more of 256 
COLCA1, COLCA2 and C11orf53 transcripts (PSMR < 10-10). There was also evidence that the 3p21.1 and 257 
19q13.33 SNPs acted through SFMBT1 and FUT2 respectively (PSMR < 10-5), as well as the 6p21.31 SNP acted 258 
through class II HLA expression (PSMR < 5 x 10-4).  259 
 260 
Based on genetic fine-mapping and functional annotation, our data indicated several candidate target genes 261 
with functions previously unconnected to colorectal tumourigenesis (Supplementary Data 9). The SFMBT1 262 
protein (3p21.1) acts as a histone reader and a component of a transcriptional repressor complex29. TNS3 at 263 
7p12.3 encodes the focal adhesion protein TENSIN3, to which the intestinal stem cell marker protein 264 
Musashi1 has been reported to bind. Tns3-null mice exhibit impaired intestinal epithelial development, 265 
probably because of defects in Rho GTPase signalling and cell adhesion30. LRP1 (12q13.3, LDL receptor-related 266 
protein 1) (Fig.3) may be involved in Wnt-signalling31, although its role in the intestines has not previously 267 
been conclusively demonstrated. FUT2 at 19q13.33 encodes fucosyltransferase II. Variation at this locus is 268 
associated with differential interactions with intestinal bacteria and viruses. Our data thus provide evidence 269 
for a role of the microbiome in CRC risk32. PTPN1 (20q13.13), also known as PTP1B, encodes a non-receptor 270 
tyrosine phosphatase involved in regulating JAK-signalling, IR, c-Src, CTNNB1, and EGFR. 271 
 272 
We annotated all risk loci with five types of functional data: (i) presence of a CHi-C contact linking to a gene 273 
promoter, (ii) presence of an association from eQTL, (iii) presence of a regulatory state, (iv) evidence of TF-274 
binding, (v) presence of a nonsynonymous coding change (Supplementary Data 9). Collectively this analysis 275 
suggested three primary candidate disease mechanisms across a number of risk loci: firstly, genes linked to 276 
BMP/TGF-β signalling (e.g. GREM1, BMP2, BMP4, SMAD7, SMAD9); secondly, genes with roles either directly 277 
or indirectly linked to MYC (e.g. MYC, TCF7L2); and thirdly genes with roles in maintenance of chromosome 278 
integrity (e.g. TERT, RTEL1) and DNA repair (e.g. POLD3) (Supplementary Figure 5). 279 
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 280 
Pathway gene set enrichment analyses33 revealed several growth or development related pathways were 281 
enriched, notably TGF-β signalling and immune response pathways (Supplementary Figure 6, Supplementary 282 
Data 10). Other cancer-related themes included apoptosis and leukocyte differentiation pathways. We used 283 
Data-driven Expression-Prioritized Integration for Complex Traits (DEPICT)34 to predict gene targets based on 284 
gene functions that are shared across genome-wide significant risk loci, as well as those associated at P < 10-5 285 
as advocated to mitigate against type II error. Tissue-specificity with respect to colonic tissue was evident 286 
(permutation test, P < 5 x 10-3) and among the protein-coding genes predicted, there was enrichment for TGF-287 
β and PI3K-signalling pathways, and abnormal intestinal crypt gene sub-networks (P < 10−5; Supplementary 288 
Data 11). 289 
 290 
Contribution of risk SNPs to heritability 291 
Using Linkage Disequilibrium Adjusted Kinships (LDAK)35 in conjunction with the GWAS data generated on 292 
unselected CRC cases (i.e. COIN, CORSA, Croatia, DACHS, FIN, SCOT, Scotland1, SOCCS/LBC, SOCCS/GS, UKBB, 293 
VQ58 studies) we estimated that the heritability of CRC attributable to all common variation is 0.29 (95% 294 
confidence interval: 0.24-0.35). To estimate the sample size required to explain a greater proportion of the 295 
GWAS heritability, we implemented a likelihood-based approach using association statistics in combination 296 
with LD information to model the effect size distribution36 which was best represented by a three-component 297 
model (mixture of two normal distributions). Under this model, to identify SNPs explaining 80% of the GWAS 298 
heritability, it is likely to require effective sample sizes in excess of 300,000 if solely based on GWAS 299 
associations (Supplementary Figure 7). 300 
 301 
After adjusting for winner’s curse37, the 79 SNPs thus far shown to be associated with CRC susceptibility in 302 
Europeans explain 11% of the 2.2-fold familial relative risk (FRR)38, whilst all common genetic variants 303 
identifiable through GWAS could explain 73% of the FRR. Thus, the identified susceptibility SNPs collectively 304 
account for approximately 15% of the FRR of CRC that can be explained by common genetic variation. We 305 
incorporated the newly-identified SNPs into risk prediction models for CRC and derived a polygenic risk score 306 
based on a total of 79 GWAS significant risk variants. Individuals in the top 1% have a 2.6-fold increased risk of 307 
CRC compared with the population average (Supplementary Figure 8). Risk re-classification using this PRS 308 
offers the prospect of optimising prevention programmes for CRC in the population, for example through 309 
targeting screening6, and also preventative interventions. The identification of further risk loci through the 310 
analysis of even larger GWAS is likely to improve the performance of any PRS model.  311 
 312 
Co-heritability with non-cancer traits 313 
We implemented cross-trait LD score regression39 to investigate co-heritability globally between CRC and 41 314 
traits with publicly available GWAS summary statistics data. None of the genetic correlations remained 315 
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significant after Bonferroni correction (two-sided Z-test, P-threshold: 0.05/41 = 1.2 x 10-3). However, 316 
nominally significant positive associations with CRC risk (Supplementary Data 12) included insulin resistance, 317 
comprising raised fasting insulin, glucose and HbA1c (positive), hyperlipidaemia, comprising raised total 318 
cholesterol and low-density lipoprotein cholesterol, and ulcerative colitis, all of which are traits or diseases 319 
previously reported in observational epidemiological studies to be associated with CRC risk40,41. 320 
 321 
 322 
323 
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DISCUSSION 324 
Here we report a comprehensive analysis that sheds new light on the molecular basis of genetic risk for a 325 
common cancer, and greatly increases the number of known CRC risk SNPs. To identify the most credible 326 
target genes at each site, we have performed detailed annotation using public databases, and have also 327 
acquired our own disease-specific data from ChIP-seq, promoter capture Hi-C, and gene expression analyses.  328 
 329 
Given that there remains significant missing common heritability for CRC, additional GWAS meta-analyses are 330 
likely to lead to discovery of more risk loci. Such an assertion is directly supported a contemporaneous study42 331 
which has reported the identification of 40 independent signals; 30 novel loci and 10 conditionally 332 
independent association signals at previously and newly identified CRC risk loci. Of these, 18 were replicated 333 
in our analysis, with an additional five exhibiting an independent signal present at the same locus 334 
(Supplementary Data 13). 335 
 336 
Overall, our findings provide new insights into the biological basis of CRC, not only confirming the importance 337 
of established gene networks, but also providing evidence that point to a role for the gut microbiome in CRC 338 
causation, and identifying several functional mechanisms previously unsuspected of any involvement in 339 
colorectal tumourigenesis. Several of the gene pathways identified through GWAS may provide potential 340 
novel targets for chemoprevention and chemotherapeutic intervention.  341 
 342 
343 
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METHODS 344 
Ethics 345 
Collection of patient samples and associated clinico-pathological information was undertaken with written 346 
informed consent and relevant ethical review board approval at respective study centres in accordance with 347 
the tenets of the Declaration of Helsinki. Specifically: (i) UK National Cancer Research Network Multi-Research 348 
Ethics Committee (02/0/097 [NSCCG], 01/0/5) [SOCCS], 05/S1401/89 [GS:SFHS], LREC/1998/4/183 [LBC1921], 349 
2003/2/29 [LBC1936], 17/SC/0079 [CORGI] and 07/S0703/136 [SCOT]); (ii) The research activities of UK 350 
Biobank were approved by the North West Multi-centre Research Ethics Committee (11/NW/0382) in relation 351 
to the process of participant invitation, assessment and follow-up procedures. Additionally, ethics approvals 352 
from the National Information Governance Board for Health & Social Care in England and Wales and approval 353 
from the Community Health Index Advisory Group in Scotland were also obtained to gain access to the 354 
information that would allow the invitation of participants. This study did not need to re-contact the 355 
participants, and no separate ethics approval was required according to the Ethics and Governance 356 
Framework (EGF) of UK Biobank; (iii) South East Ethics Committee MREC (03/1/014); (iv) Written informed 357 
consent was obtained from all participants of CORSA. The study was approved by the ethical review 358 
committee of the Medical University of Vienna (MUW, EK Nr. 703/2010) and the “Ethikkommission 359 
Burgenland” (KRAGES, 33/2010); (v) Finnish National Supervisory Authority for Welfare and Health, National 360 
Institute for Health and Welfare (THL/151/5.05.00/2017), the Ethics Committee of the Hospital District of 361 
Helsinki and Uusimaa (HUS/408/13/03/03/09). 362 
The diagnosis of colorectal cancer (ICD-9 153, 154; ICD10 C18.9, C19, C20) was established in all cases in 363 
accordance with World Health Organization guidelines.  364 
 365 
Primary GWAS 366 
We analysed data from 5 primary GWAS (Supplementary Data 2 and Supplementary Data 3): 367 
(1) The NSCCG-OncoArray GWAS comprised 6,240 cases ascertained through the National Study of Colorectal 368 
Cancer Genetics (NSCCG)43 and 1,041 cases collected through the CORGI consortium, genotyped using the 369 
Illumina OncoArray. Patients were selected for having a family history of CRC (at least one first degree 370 
relative) or age of diagnosis below 58. Controls were also genotyped using the OncoArray and comprised (i) 371 
3,031 cancer-free men recruited by the PRACTICAL Consortium - the UK Genetic Prostate Cancer Study 372 
(UKGPCS) (age <65 years), a study conducted through the Royal Marsden NHS Foundation Trust and SEARCH 373 
(Study of Epidemiology & Risk Factors in Cancer), recruited via GP practices in East Anglia (2003-2009), and (ii) 374 
4,488 cancer-free women across the UK, recruited via the Breast Cancer Association Consortium (BCAC).  375 
(2) The SCOT GWAS comprised 3,076 cases from the Short Course Oncology Treatment (SCOT) trial – a study 376 
of adjuvant chemotherapy in colorectal cancer by the CACTUS and OCTO groups44. Controls comprised 4,349 377 
cancer-free individuals from The Heinz Nixdorf Recall study45. Both cases and controls were genotyped using 378 
the Illumina Global Screening Array. 379 
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(3) SOCCS/Generation Scotland (SOCCS/GS) comprised 4,772 cases from the Study of Colorectal Cancer in 380 
Scotland (SOCCS)12,13 and 12,158 controls including 2,221 population based controls from SOCCS and 381 
additional 9,937 population controls without prior history of colorectal cancer from Generation Scotland-382 
Scottish Family Health Study (GS:SFHS)46.  383 
(4) SOCCS/Lothian Birth Cohort (SOCCS/LBC) GWAS comprised 1,037 cases from the Study of Colorectal 384 
Cancer in Scotland (SOCCS)47 and 1,522 population-based controls without prior history of malignant tumours 385 
from the Lothian Birth Cohorts (LBC) of 1921 and 193648. 386 
(5) UK Biobank (UKBB) GWAS comprised 6,360 cases and 25,440 population based control individuals. UK 387 
Biobank is a large cohort study with more than 500,000 individuals recruited. Biological samples of these 388 
participants were genotyped using the custom-designed Affymetrix UK BiLEVE Axiom array on an initial 50,000 389 
participants and Affymetrix UK Biobank Axiom array on the remaining 450,000 participants. The two arrays 390 
had over 95% common content. Genotyping was done at the Affymetrix Research Services Laboratory in Santa 391 
Clara, California, USA. Details on genotyping and quality control were previously reported49. Self-reported 392 
cases of cancers of bowel, colon or rectum, if not confirmed by the ICD9 or ICD10 codes were excluded from 393 
the analysis. Healthy control individuals without history of cancer and/or colorectal adenoma were included in 394 
the analysis after matching one case to four controls by age, gender, date of blood draw, ethnicity and region 395 
of residence (two first letters of postal code).  396 
 397 
Published GWAS  398 
We made use of 10 previously published GWAS (Supplementary Data 2): (1) UK1 (CORGI study) comprised 399 
940 cases with colorectal neoplasia and 965 controls12; (2) Scotland1 (COGS study) included 1,012 CRC cases 400 
and 1,012 controls12; (3) VQ58 comprised 1,800 cases from the UK-based VICTOR and QUASAR2 adjuvant 401 
chemotherapy clinical trials and 2690 population control genotypes from the Wellcome Trust Case Control 402 
Consortium 2 (WTCCC2) 1958 birth cohort50; (4) CCFR1 comprised 1,290 familial CRC cases and 1,055 controls 403 
from the Colon Cancer Family Registry (CCFR)15; (5) CCFR2 included a further 796 cases from the CCFR and 404 
2,236 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) studies of breast and prostate 405 
cancer51,52; (6) COIN was based on 2,244 CRC cases ascertained through two independent Medical Research 406 
Council clinical trials of advanced/metastatic CRC (COIN and COIN-B)53 and controls comprised 2,162 407 
individuals from the UK Blood Service Control Group genotyped as part of the WTCCC2; (7) Finnish GWAS 408 
(FIN)3 was based on 1,172 CRC cases and 8,266 cancer free controls ascertained through FINRISK, Health 2000, 409 
Finnish Twin Cohort and Helsinki Birth Cohort Studies; (8) CORSA (COloRectal cancer Study of Austria) a 410 
molecular epidemiological study of 978 cases and 855 colonoscopy-negative controls54; (9) DACHS 411 
(Darmkrebs: Chancen der Verhütung durch Screening)55 based on 1,105 cases and 700 controls; and (10) 412 
Croatia consisted of 764 cases and 460 population-based controls56.  413 
The VQ58, UK1 and Scotland1 GWAS were genotyped using Illumina Hap300, Hap240S, Hap370, Hap550 or 414 
Omni2.5M arrays. 1958BC genotyping was performed as part of the WTCCC2 study on Hap1.2M-Duo Custom 415 
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arrays. The CCFR samples were genotyped using Illumina Hap1M, Hap1M-Duo or Omni-express arrays. CGEMS 416 
samples were genotyped using Illumina Hap300 and Hap240 or Hap550 arrays. The COIN cases were 417 
genotyped using Affymetrix Axiom Arrays and the Blood Service controls were genotyped using Affymetrix 6.0 418 
arrays. FIN cases were genotyped using Illumina HumanOmni 2.5M8v1 and controls using Illumina HumanHap 419 
670k and 610k arrays. DACHS study samples were genotyped using the Illumina OncoArray, CORSA study 420 
sampels were genotyped on the Affymetrix Axiom Genome-Wide CEU 1 Array, and Croatia study samples 421 
were genotyped on Illumina OmniExpressExome BeadChip 8v1.1 or 8v1.3.  422 
 423 
Quality control 424 
Standard quality-control (QC) measures were applied to each GWAS8. Specifically, individuals with low SNP 425 
call rate (<95%) as well as individuals evaluated to be of non-European ancestry (using the HapMap version 2 426 
CEU, JPT/CHB and YRI populations as a reference) were excluded (Supplementary Figure 9). For apparent 427 
first-degree relative pairs, we excluded the control from a case-control pair; otherwise, we excluded the 428 
individual with the lower call rate. SNPs with a call rate <95% were excluded as were those with a MAF < 0.5% 429 
or displaying significant deviation from Hardy-Weinberg equilibrium (P < 10−5). QC details are provided in 430 
Supplementary Data 3. All genotype analyses were performed using PLINK v1.957. 431 
 432 
Imputation and statistical analysis 433 
Prediction of the untyped SNPs was carried out using SHAPEIT v2.83758 and IMPUTE v2.3.259. The CCFR1, 434 
CCFR2, COIN, CORSA, Croatia, NSCCG-OncoArray, SCOT, Scotland1, SOCCS/GS, SOCCS/LBC, UK1, and VQ58 435 
samples used a merged reference panel using data from 1000 Genomes Project (phase 1, December 2013 436 
release) and UK10K (April 2014 release). Imputation of UKBB was based on data from 1000 Genomes Project 437 
(phase 3), UK10K, and Haplotype Reference Consortium. The FIN and DACHS GWAS were imputed using a 438 
reference panel comprised of 1000 Genomes Projects Project with an additional population matched 439 
reference panel: 3,882 Sequencing Initiative Suomi (SISu) haplotypes for the FIN study, and 3,000 sequenced 440 
CRC cases for the DACHS study. We imposed predefined thresholds for imputation quality to retain potential 441 
risk variants with MAF >0.5% for validation. Poorly imputed SNPs defined by an information measure <0.80 442 
were excluded. Tests of association between imputed SNPs and CRC were performed under an additive 443 
genetic model in SNPTEST v2.5.260. Principal components were added to adjust for population stratification 444 
where required (i.e. DACHS, FIN, NSCCG-OncoArray, SCOT, and UKBB). 445 
To determine whether specific coding variants within HLA genes contributed to the diverse association 446 
signals, we imputed the classical HLA alleles (A, B, C, DQA1, DQB1, and DRB1) and coding variants across the 447 
HLA region using SNP2HLA11. The imputation was based on a reference panel from the Type 1 Diabetes 448 
Genetics Consortium (T1DGC) consisting of genotype data from 5,225 individuals of European descent with 449 
genotyping data of 8,961 common SNPs and indel polymorphisms across the HLA region, and four digit 450 
genotyping data of the HLA class I and II molecules. For the X chromosome, genotypes were phased and 451 
15 
 
imputed as for the autosomal chromosome, with the inclusion of the “chrX” flag. X chromosome association 452 
analysis was performed in SNPTEST using a maximum likelihood model, assuming complete inactivation of 453 
one allele in females and equal effect size between males and females. 454 
The adequacy of the case-control matching and possibility of differential genotyping of cases and controls was 455 
evaluated using a Q-Q plot of test statistics in individual studies (Supplementary Figure 1). Meta-analyses 456 
were performed using the fixed-effects inverse-variance method using META v1.761. Cochran's Q-statistic to 457 
test for heterogeneity and the I2 statistic to quantify the proportion of the total variation due to heterogeneity 458 
were calculated. A Q-Q plot of the meta-analysis test statistics was also performed (Supplementary Figure 1). 459 
None of the studies showed evidence of genomic inflation, where λGC values for the CCFR1, CCFR2, COIN, 460 
CORSA, Croatia, DACHS, FIN, NSCCG-OncoArray, SCOT, Scotland1, SOCCS/GS, SOCCS/LBC, UKBB, UK1, and 461 
VQ58 studies were 1.03, 1.08, 1.09, 1.11, 1.01, 1.01, 1.09, 1.10, 1.08, 1.02, 1.09, 1.04, 1.05, 1.02, and 1.06 462 
respectively. Estimates were calculated using the regression method, as implemented in GenABEL. 463 
 464 
Definition of known and new risk loci 465 
We sought to identify all associations for CRC previously reported at a significance level P < 5 × 10−8 by 466 
referencing the NHGRI-EBI Catalog of published genome-wide association studies, and a literature search for 467 
the years 1998-2018 using PubMed (performed January 2018). Additional articles were ascertained through 468 
references cited in primary publications. Where multiple studies reported associations in the same region, we 469 
only considered the first reported genome-wide significant association. New loci were identified based on 470 
SNPs at P < 5 × 10−8 using the meta-analysis summary statistics, with LD correlations from a reference panel of 471 
the European 1000 Genomes Project samples combined with UK10K. We only included one SNP per 500kb 472 
interval. To measure the probability of the hits being false positives, the Bayesian False-Discovery Probability 473 
(BFDP)9 was calculated based on a plausible OR of 1.2 (based on the 95th percentile of the meta-analysis OR 474 
values) and a prior probability of association of 10−5. A conditional analysis was performed using Genome-475 
wide Complex Trait Analysis (GCTA)62, conditioning on the new and known SNPs, and SNPs with Pconditioned < 5 x 476 
10-8 and r2 > 0.1 were clumped using PLINK. The NSCCG-Oncoarray data were used to provide the LD 477 
reference data. 478 
 479 
Fidelity of imputation 480 
The reliability of imputation of the novel risk SNPs identified (all with an IMPUTE2 r2 > 0.80) was assessed for 481 
51 SNPs (comprising all new signals not directly genotyped) by examining the concordance between imputed 482 
and whole-genome sequenced genotypes in a subset of 201 samples from the CORGI and NSCCG studies. 483 
>98% concordance was found between the directly sequenced and imputed SNPs (Supplementary Data 14). 484 
 485 
eQTL analysis 486 
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In the INTERMPHEN study, biopsies of normal colorectal mucosa (trios of rectum, proximal colon and distal 487 
colon) were obtained from 131 UK individuals with self-reported European ancestry without CRC. Genotyping 488 
was performed using the Illumina Infinium Human Core Exome array, with quality control and imputation as 489 
above. RNA-seq was performed and data analysed as per the GTEx Project pipeline v7 using the 1000 490 
Genomes and UK10K data as reference. Gene-level expression quantification was based on the GENCODE 19 491 
annotation, collapsed to a single transcript model for each gene using a custom isoform procedure. Gene-492 
level quantification (read counts and TPM values) was performed with RNA-SeQC v1.1.8. Gene expression was 493 
normalised using the TMM algorithm, implemented in edgeR, with inverse normal transformation, based on 494 
gene expression thresholds of >0.1 Transcripts Per Million (TPM) in ≥20% of samples and ≥6 reads in ≥20% of 495 
samples. cis-eQTL mapping was performed separately for proximal colon, distal colon and rectum samples 496 
using FastQTL. Principal components for the SNP data and additional covariate factors were identified using 497 
Probabilistic Estimation of Expression Residuals (PEER). P-values were generated for each variant-gene pair 498 
testing alternative hypothesis that the slope of a linear regression model between genotype and expression 499 
deviates from 0. The mapping window was defined as 1Mb either side of the transcription start site. Beta 500 
distribution-adjusted empirical P-values from FastQTL were used to calculate Q-values, and FDR threshold of 501 
≤0.05 was applied to identify genes with a significant eQTL. The normalised effect size (NES) of the eQTLs was 502 
defined as the slope of the linear regression, and computed as the effect of the alternative allele (ALT) relative 503 
to the reference allele (REF) in the human genome reference GRCh37/hg19). MetaTissue was used to 504 
generate a “pan-colonic” eQTL measure from the three individual RNA-seq datasets per patient.  505 
To supplement this analysis, we performed Summary-data-based Mendelian Randomization (SMR) analysis28 506 
including all eQTLs with nominally significant associations (P < 0.05). We additionally examined for 507 
heterogeneity using the heterogeneity in dependent instruments (HEIDI) test, where PHEIDI < 0.05 were 508 
considered as reflective of heterogeneity and were excluded.  509 
 510 
Promoter capture Hi-C 511 
In situ promoter capture Hi-C (CHi-C) on LoVo and HT29 cell lines was performed as previously described63. Hi-512 
C and CHi-C libraries were sequenced using HiSeq 2000 (Illumina). Reads were aligned to the GRCh37 build 513 
using bowtie2 v2.2.6 and identification of valid di-tags was performed using HiCUP v0.5.9. To declare 514 
significant contacts, HiCUP output was processed using CHiCAGO v1.1.8. For each cell line, data from three 515 
independent biological replicates were combined to obtain a definitive set of contacts. As advocated, 516 
interactions with a score ≥ 5.0 were considered to be statistically significant64. 517 
 518 
Chromatin state annotation 519 
Colorectal cancer risk loci and SNPs in LD (r2 > 0.8) were annotated for putative functional effect based upon 520 
ChIP-seq H3K4me1 (C15410194), H3K9me3 (C15410193), H3K27me3 (C15410195) and H3K36me3 521 
(C15410192) for LoVo, and H3K4me1 and H3K9me3 for HT29. ChIP libraries were sequenced using HiSeq 2000 522 
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(Illumina) with 100bp single-ended reads. Generated raw reads were filtered for quality (Phred33 ≥ 30) and 523 
length (n ≥ 32), and adapter sequences were removed using Trimmomatic v0.22. Reads passing filters were 524 
then aligned to the human reference (hg19) using BWA v0.6.1. Peak calls are obtained using MACS2 v 525 
2.0.10.07132012. 526 
 527 
Histone mark and transcription factor enrichment analysis 528 
ChIP-seq data from colon crypt and tumour samples was obtained for H3K27ac and H3K4me165. Multiple 529 
samples of the same tissue type or tumour stage were merged together. Additional ChIP-seq data from the 530 
Roadmap Epigenomics project21 was obtained for H3K4me3, H3K27ac, H3K4me1, H3K27me3, H3K9ac, 531 
H3K9me3 and H3K36me3 marks in up to 114 tissues. Overlap enrichment analysis of CRC risk SNPs with these 532 
peaks was performed using EPIGWAS, as described by Trynka et al20. Briefly, we evaluated if CRC risk SNPs and 533 
SNPs in LD (r2 > 0.80) with the sentinel SNP, were enriched at ChIP-seq peaks in tissues by a permutation 534 
procedure with 105 iterations.  535 
To examine enrichment in specific TF binding across risk loci, we adapted the variant set enrichment method 536 
of Cowper-Sal lari et al.22 Briefly, for each risk locus, a region of strong LD (defined as r2 > 0.8 and D′ > 0.8) was 537 
determined, and these SNPs were termed the associated variant set (AVS). ChIP-seq uniform peak data were 538 
obtained for LoVo and HT29 cell lines (198 and 29 experiments respectively)66 and the above described 539 
histone marks. For each of these marks, the overlap of the SNPs in the AVS and the binding sites was 540 
determined to produce a mapping tally. A null distribution was produced by randomly selecting SNPs with the 541 
same characteristics as the risk-associated SNPs, and the null mapping tally calculated. This process was 542 
repeated 105 times, and P-values calculated as the proportion of permutations where the null mapping tally 543 
was greater or equal to the AVS mapping tally. An enrichment score was calculated by normalising the tallies 544 
to the median of the null distribution. Thus, the enrichment score is the number of standard deviations of the 545 
AVS mapping tally from the median of the null distribution tallies.  546 
 547 
Functional annotation 548 
For the integrated functional annotation of risk loci, LD blocks were defined as all SNPs in r2 > 0.8 with the 549 
sentinel SNP. Risk loci were then annotated with five types of functional data: (i) presence of a CHi-C contact 550 
linking to a gene promoter, (ii) presence of an association from eQTL, (iii) presence of a regulatory state, (iv) 551 
evidence of TF-binding, and (v) presence of a nonsynonymous coding change. Candidate causal genes were 552 
then assigned to CRC risk loci using the target genes implicated in annotation tracks (i), (ii), (iiii) and (iv). If the 553 
data supported multiple gene candidates, the gene with the highest number of individual functional data 554 
points was considered as the candidate. Where multiple genes had the same number of data points, all genes 555 
were listed. Direct non-synonymous coding variants were allocated additional weighting. Competing 556 
mechanisms for the same gene (e.g. both coding and promoter variants) were allowed for. Finally, if no 557 
evidence was provided by these criteria, if the lead SNP was intronic we assigned candidacy on this basis, or if 558 
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intergenic the nearest gene neighbour. Chromatin data were obtained from HaploReg v4 and regulatory 559 
regions from Ensembl. 560 
Regional plots were created using visPIG67, using the data described above. We used ChromHMM to integrate 561 
DNAse, H3K4me3, H3K4me1, H3K27ac, Pol2 and CTCF states from the CRC cell line HCT116 using a 562 
multivariate Hidden Markov Model68. Chromatin annotation tracks for colonic mucosa (E075), rectal mucosa 563 
(E101) and sigmoid colon (E106) were obtained from the Roadmap Epigenomics project21, using the core 15-564 
state model data based on H3K4me3, H3K4me1, H3K36me3, H3K27me3 and H3K9me3 marks. 565 
 566 
Transcription factor binding disruption analysis 567 
To determine if the risk variants or their proxies were disrupting motif binding sites, we used the motifbreakR 568 
package69. This tool predicts the effects of variants on TF binding motifs, using position probability matrices to 569 
determine the likelihood of observing a particular nucleotide at a specific position within a TF binding site. We 570 
tested the SNPs by estimating their effects on over 2,800 binding motifs as characterised by ENCODE, 571 
FactorBook, HOCOMOCO and HOMER. Scores were calculated using the relative entropy algorithm. 572 
 573 
Heritability analysis 574 
LD Score regression70 was used to determine the amount of inflation due to causes other than polygenic 575 
heritability. This is calculated as the ratio of the LD Score regression intercept with the mean χ2 statistic. 576 
We used LDAK35 to estimate the polygenic variance (i.e. heritability) ascribable to SNPs from summary statistic 577 
data for the GWAS datasets which were based on unselected cases (i.e. CORSA, COIN, Croatia, DACHS, FIN, 578 
SCOT, Scotland1, SOCCS/GS, SOCCS/LBC, UKBB, and VQ58). SNP-specific expected heritability, adjusted for LD, 579 
MAF and genotype certainty, was calculated from the UK10K and 1000 Genomes data. Individuals were 580 
excluded if they were closely related, had divergent ancestry from CEU, or had a call rate <0.99. SNPs were 581 
excluded if they showed deviation from HWE with P < 1 × 10−5, genotype yield <95%, MAF <1%, SNP 582 
imputation score <0.99, and the absence of the SNP in the GWAS summary statistic data. This resulted in a 583 
total 6,024,731 SNPs used to estimate the heritability of CRC. 584 
To estimate the sample size required to detect a given proportion of the GWAS heritability we implemented a 585 
likelihood-based approach to model the effect-size distribution36, using association statistics from the meta-586 
analysis, and LD information from individuals of European ancestry in the 1000 Genomes Project Phase 3. LD 587 
values were based on an r2 threshold of 0.1 and a window size of 1MB. The goodness of fit of the observed 588 
distribution of P-values against the expected from a two-component model (single normal distribution) and a 589 
three-component model (mixture of two normal distributions) were assessed, and a better fit was observed 590 
for the latter model. The percentage of GWAS heritability explained for a projected sample size was 591 
determined using this model, based on power calculations for the discovery of genome-wide significant SNPs. 592 
The genetic variance explained was calculated as the proportion of total GWAS heritability explained by SNPs 593 
19 
 
reaching genome-wide significance at a given sample size. The 95% confidence intervals were determined 594 
using 105 simulations. 595 
 596 
Cross-trait genetic correlation 597 
LD score regression39 was used to determine if any traits were correlated with CRC risk. GWAS summary data 598 
was obtained for allergy, asthma, coronary artery disease, fatty acids, lipids (total cholesterol, high density 599 
lipoprotein, low density lipoprotein, triglycerides), auto-immune diseases (Crohn's disease, rheumatoid 600 
arthritis, atopic dermatitis, celiac disease, multiple sclerosis, primary biliary cirrhosis, inflammatory bowel 601 
disease, ulcerative colitis, systemic lupus erythematosus), anthropometric measures (BMI, height, body fat), 602 
glucose sensitivity (fasting glucose, fasting insulin, HbA1c), childhood measures (birth weight, birth length, 603 
childhood obesity, childhood BMI), eGFR, and type 2 diabetes. All data was obtained for European 604 
populations. Summary statistics were reformatted to be consistent, and constrained to HapMap3 SNPs as 605 
these have been found to generally impute well. LD Scores were determined using 1000 Genomes European 606 
data. 607 
 608 
Familial risk explained by risk SNPs 609 
Under a multiplicative model, the contribution of risk SNPs to the familial risk of CRC was calculated from 610 
∑ ୪୭୥ೖ୪୭୥ బ௞  , where 0 is the familial risk to first-degree relatives of CRC cases, assumed to be 2.2
38, and k is the 611 
familial relative risk associated with SNP k, calculated as ௞ = ௣ೖ௥ೖ
మା௤ೖ
(௣ೖ௥ೖା௤ೖ)మ, where pk is the risk allele frequency 612 
for SNP k, qk = 1−pk , and rk is the estimated per-allele OR from the meta-analysis71. The OR estimates were 613 
adjusted for the winner’s curse using the FDR Inverse Quantile Transformation (FIQT) method37. We 614 
constructed a polygenic risk score (PRS) including all 79 CRC risk SNPs discovered or validated by this GWAS in 615 
the risk-score modelling. The distribution of risk on an RR scale in the population is assumed to be log-normal 616 
with arbitrary population mean μ set to -σ2/2 and variance ߪଶ = 2∑ ݌௞(1 − ݌௞)ߚଶ௞  where β and p 617 
correspond to the log odds ratio and the risk allele frequency, respectively, for SNP k. The distribution of PRS 618 
among cases is right-shifted by σ2 so that the overall mean PRS is 1.072. The risk distribution was also 619 
performed assuming all common variation, using ߪଶ = log(ߣ௦௜௕ଶ ), where λsib = 1.79, as determined using the 620 
heritability estimate from GCTA. 621 
 622 
Pathway analysis 623 
SNPs were assigned to genes as described in the functional annotation section. The genes that mapped to 624 
genome-wide significant CRC risk SNPs were analysed using InBio Map, a manually curated database of 625 
protein-protein interactions.  626 
Gene set enrichment was calculated using GenGen. Enrichment scores were calculated using the meta-627 
analysis results and were based on 103 permutations on the χ2 values between SNPs. Pathway definitions 628 
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were obtained from the Bader Lab33, University of Toronto, July 2018 release. This data contained pathway 629 
information from Gene Ontology (GO), Reactome, HumanCyc, MSigdb C2 (curated dataset), NCI Pathway, 630 
NetPath, and PANTHER for a total of 7,269 pathways. GO annotations that were inferred computationally 631 
were excluded. To avoid biasing the results, the meta-analysis SNPs were pruned to only those with an r2 < 0.1 632 
and a distance greater than 500kb. Pathways were visualised using Cytoscape v3.6.1, together with the 633 
EnrichmentMap v3.1.0 and AutoAnnotate v1.2 plugins. Only pathways with an FDR < 0.05 and edges with a 634 
similarity coefficient (number of shared genes between pathways) > 0.55 were displayed. 635 
 636 
Code availability 637 
All bioinformatics and statistical analysis tools used are open source. 638 
 639 
Data availability  640 
The SCOT data can be requested through the TransSCOT committee according to the ethical permissions 641 
obtained as part of the clinical trial approval (https://www.oncology.ox.ac.uk/trial/scot). The PRACTICAL and 642 
BCAC consortium control data is available through the respective Data Access Coordination Committees 643 
(http://practical.icr.ac.uk and http://bcac.ccge.medschl.cam.ac.uk/) and the Heinz Nixdorf Recall Study 644 
control data can be requested through https://www.uni-due.de/recall-studie/die-studien/hnr/. UK Biobank 645 
data can be obtained through http://www.ukbiobank.ac.uk/. The Colon Cancer Family Registry data can be 646 
obtained through http://coloncfr.org/. Finnish cohort samples can be requested from THL Biobank 647 
https://thl.fi/en/web/thl-biobank. Hi-C data have been deposited in EGA under accession number 648 
EGAS00001002614. The accession number for the ChIP-seq data reported in this paper is EGAS00001002414. 649 
The remaining data are contained within the Supplementary Files or available from the authors upon 650 
reasonable request. 651 
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FIGURE LEGENDS 1055 
 1056 
Figure 1 Study design. 1057 
 1058 
Figure 2 Manhattan plot showing all loci containing genetic risk variants independently associated with 1059 
colorectal cancer risk at P < 5 × 10−8 in European populations. SNPs on the left of the plot are new SNPs 1060 
identified in this study, and SNPs on the right were identified in previous studies and replicated at genome-1061 
wide significance in this study. The 79 risk SNPs consisted of 31 previously reported SNPs, 39 new risk 1062 
SNPs, and nine SNPs previously identified in Asian but not in European populations (denoted in dark gold). 1063 
Dotted lines indicate SNPs that were identified as independent through conditional analysis. Square 1064 
brackets indicate the position of the sentinel SNP relative to nearest genes (“gene1-[]-gene2” for 1065 
intergenic SNPs, “[gene]” for intragenic SNPs). The distance from the sentinel SNP to each gene is 1066 
proportional to the number of dashes. The red line indicates the genome-wide significance threshold. The 1067 
x-axis represents the −log10 P-values of the SNPs, and the y-axis represents the chromosomal positions. 1068 
 1069 
Figure 3 Regional plots of exemplar colorectal cancer risk loci. In the main panel, −log10 P-values (y-axis) of 1070 
the SNPs are shown according to their chromosomal positions (x-axis). The colour intensity of each symbol 1071 
reflects the extent of LD with the top SNP: white (r2 = 0) through to dark red (r2 = 1.0), with r2 estimated 1072 
from EUR 1000 Genomes data. Genetic recombination rates (cM/Mb) are shown with a light blue line. 1073 
Physical positions are based on GRCh37 of the human genome. Where available, the upper panel shows 1074 
Hi-C contacts from HT29 or LoVo. The lower panel shows the chromatin state segmentation track from the 1075 
Roadmap Epigenomics project (colonic mucosa, rectal mucosa, sigmoid colon), and HCT116. Also shown 1076 
are the relative positions of genes and transcripts mapping to each region of association. (a) rs12255141 1077 
(10q25.2); (b) rs12979278 (19q13); (c) rs2735940 (5p15); (d) rs7398375 (12q13.3). 1078 
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Table 1: Summary results for the new colorectal cancer risk loci in Europeans.  79 
 80 
SNP Cytoband position (bp, 
GRCh37) 
Risk/Alt 
Allele 
RAF OR 95% CI P-value BFDP I2 
(%) 
Phet Average 
info score 
rs61776719 1p34.3 38,461,319  C/A 0.45 1.07 (1.05; 1.10) 2.19x10-10 1.98x10-3 1  0.44 0.89
rs12143541 1p32.3 55,247,852  G/A 0.15 1.10 (1.06; 1.13) 9.44x10-10 7.44x10-3 16 0.28 0.95
rs11692435 2q11.2 98,275,354  G/A 0.90 1.12 (1.07; 1.16) 1.22x10-8 0.079 29 0.14 0.97 
rs11893063 2q33.1 199,601,925  A/G 0.47 1.07 (1.04; 1.09) 9.34x10-9 0.069 43 0.04 0.96 
rs7593422 2q33.1 200,131,695  T/A 0.55 1.07 (1.05; 1.10) 3.56x10-11 3.50x10-4 15 0.28 0.99 
rs9831861 3p21.1 53,088,285  G/T 0.59 1.07 (1.05; 1.09) 4.17x10-10 3.72x10-3 0 0.87 0.99
rs12635946 3q13.2 112,916,918  C/T 0.62 1.08 (1.06; 1.10) 1.02x10-11 1.03x10-4 11 0.33 0.97
rs17035289 4q24 106,048,291  T/C 0.83 1.10 (1.07; 1.13) 2.73x10-10 2.30x10-3 0 0.95 1.00 
rs75686861 4q31.21 145,621,328  A/G 0.10 1.12 (1.08; 1.16) 1.76x10-9 0.014 0 0.49 0.92 
rs2070699 6p24.1 12,292,772  T/G 0.48 1.07 (1.04; 1.09) 3.88x10-9 0.031 29 0.14 0.95 
rs3131043 6p21.33 30,758,466  G/A 0.43 1.07 (1.05; 1.1) 2.67x10-8 0.159 60 0.01 0.91 
rs9271770 6p21.32 32,594,248  A/G 0.81 1.08 (1.05; 1.11) 3.60x10-8 0.192 0 0.91 0.93
rs6928864 6q21 105,966,894  C/A 0.91 1.13 (1.09; 1.19) 1.37x10-8 0.094 0 0.73 0.98
rs10951878 7p12.3 46,926,695  C/T 0.49 1.06 (1.04; 1.09) 1.10x10-8 0.080 0 0.65 0.99 
rs3801081 7p12.3 47,511,161  G/A 0.68 1.08 (1.06; 1.11) 2.00x10-11 1.96x10-4 50 0.01 1.00 
rs1412834 9p21.3  22,110,131  T/C 0.50 1.08 (1.06; 1.11) 4.13x10-14 5.05x10-7 14 0.30 1.00 
rs4450168 11p15.4 10,286,755  C/A 0.17 1.10 (1.06; 1.13) 1.24x10-8 0.079 0 0.81 0.86 
rs7398375 12q13.3 57,540,848  C/G 0.72 1.09 (1.06; 1.13) 3.91x10-10 3.23x10-3 0 0.93 0.83
rs12427600 13q13.3 37,460,648  C/T 0.24 1.09 (1.06; 1.11) 5.43x10-11 5.01x10-4 0 0.81 0.99
rs45597035 13q22.1 73,649,152  A/G 0.64 1.08 (1.05; 1.10) 2.16x10-10 1.94x10-3 0 0.53 0.96 
rs1330889 13q22.3 78,609,615  C/T 0.87 1.11 (1.07; 1.14) 6.50x10-10 5.25x10-3 0 0.59 0.97 
rs7993934 13q34 111,074,915  T/C 0.65 1.08 (1.05; 1.10) 3.03x10-11 2.94x10-4 0 0.55 0.99 
rs4776316 15q22.31 67,007,813  A/G 0.73 1.08 (1.05; 1.10) 1.11x10-8 0.076 22 0.21 0.95 
rs10152518 15q23 68,177,162  G/A 0.19 1.08 (1.05; 1.11) 3.24x10-8 0.180 0 0.84 0.97
rs7495132 15q26.1 91,172,901  T/C 0.12 1.11 (1.07; 1.14) 7.92x10-10 6.34x10-3 29 0.14 0.99
rs61336918 16q23.2 80,007,266  A/T 0.29 1.09 (1.06; 1.12) 2.04x10-12 2.14x10-5 0 0.90 0.99 
rs1078643 17p12 10,707,241  A/G 0.77 1.09 (1.06; 1.12) 4.14x10-11 3.81x10-4 0 0.56 0.92 
rs285245 19p13.11 16,420,817  T/C 0.11 1.11 (1.07; 1.15) 3.71x10-8 0.195 2 0.42 0.91 
rs12979278 19q13.33 49,218,602  T/C 0.53 1.07 (1.05; 1.09) 6.11x10-10 5.35x10-3 15 0.28 0.96
rs6066825 20q13.13 47,340,117  A/G 0.65 1.10 (1.08; 1.13) 3.82x10-17 5.67x10-10 0 0.49 0.99
rs3787089 20q13.33 62,316,630  C/T 0.32 1.07 (1.05; 1.10) 5.80x10-9 0.043 0 0.80 0.96
Associations previously only identified in Asian populations  
rs639933 5q31.1 134,467,751  C/A 0.38 1.07 (1.05; 1.10) 1.14x10-9 9.50x10-3 0 0.73 0.98 
rs6933790 6p21.1 41,672,769  T/C 0.83 1.10 (1.07; 1.14) 3.65x10-10 3.03x10-3 21 0.23 0.91 
rs704017 10q22.3 80,819,132  G/A 0.60 1.10 (1.08; 1.13) 2.96x10-16 4.15x10-9 23 0.21 0.95 
rs12255141 10q25.2 114,294,892  G/A 0.10 1.11 (1.07; 1.15) 2.97x10-9 0.022 0 0.81 0.96
rs10849438 12p13.31 6,412,036  G/T 0.12 1.12 (1.08; 1.16) 1.04x10-10 9.49x10-4 21 0.23 0.95
rs73975588 17p13.3 816,741  A/C 0.87 1.10 (1.06; 1.13) 8.71x10-9 0.058 33 0.11 0.97 
rs9797885 19q13.2 41,873,001  G/A 0.71 1.08 (1.05; 1.10) 2.77x10-10 2.43x10-3 0 0.70 0.99 
rs6055286 20p12.3 7,718,045  A/G 0.15 1.11 (1.07; 1.14) 9.69x10-11 8.61x10-4 50 0.02 0.97 
rs2179593 20q13.12 42,660,286  A/C 0.72 1.07 (1.05; 1.10) 4.62x10-9 0.035 0 0.67 0.97 
 81 
RAF: risk allele frequency in Europeans; OR, odds ratio; CI, confidence interval; BFDP, Bayesian False Discovery 82 
Probability; I2, proportion of the total variation due to heterogeneity; Phet, P-value for heterogeneity. BFDP calculated 83 
using prior = 10-5 and maximum relative risk = 1.2. 84 
  85 
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 86 
Table 2: Colorectal cancer variants identified in analysis conditioning on the sentinel SNP at each risk locus.  87 
 88 
 Conditional  
(Sentinel) 
SNPs 
Cytoband 
(position 
(bp, 
GRCh37)) 
Risk/
Alt 
Allele 
RAF OR
 (95% CI) 
P-value Condition
al OR 
(95% CI) 
Condition
al P-value 
BFDP LD with 
sentinel 
SNP 
(r2;D’) 
I2 
(%) 
Phet Average 
info 
score 
rs77776598 
(rs2735940) 
5p15.33 
(1,240,998) 
C/T 0.06 1.14 
(1.09;1.20) 
7.90x10-9 1.16 
(1.11;1.21) 
2.84x10-10 0.003 0.00; 
0.33 
0 0.93 0.99
rs4944940 
(rs3824999) 
11q13.4 
(74,415,252) 
G/A 0.96 1.31 
(1.24;1.39) 
1.05x10-20 1.28 
(1.21;1.35) 
3.21x10-17 2.73x10-9 0.00; 
0.19 
6 0.38 0.95
rs12818766 
(rs3217810) 
12p13.32 
(4,376,091) 
A/G 0.18 1.10 
(1.07;1.13) 
2.15x10-9 1.10 
(1.07;1.13) 
5.29x10-9 0.037 0.00; 
0.06 
30 0.16 0.89 
rs1570405 a 
(rs4444235) 
14q22.2 
(54,554,234) 
G/A 0.31 1.06 
(1.03;1.08) 
9.81x10-7 1.07 
(1.04;1.09) 
1.91x10-8 0.125 0.02; 
0.19 
0 0.46 1.00 
rs16969681 b 
(rs73376930) 
15q13.3 
(32,993,111) 
T/C 0.09 1.22 
(1.18;1.27) 
2.97x10-27 1.21 
(1.16;1.25) 
2.85x10-24 1.33x10-
16 
0.01; 
0.32 
42 0.04 0.99 
rs16959063 
(rs73376930) 
15q13.3 
(33,105,730) 
A/G 0.01 1.30 
(1.18;1.42) 
3.72x10-8 1.33 
(1.21;1.45) 
5.40x10-9 0.23 0.00; 
0.40 
30 0.13 0.96 
rs17816465 
(rs73376930) 
15q13.3 
(33,156,386) 
A/G 0.20 1.11 
(1.08;1.14) 
1.12x10-14 1.12 
(1.09;1.15) 
8.36x10-15 1.07x10-7 0.00; 
0.11 
44 0.04 0.97
rs899244 
(rs2696839) 
16q24.1 
(86,700,030) 
T/C 0.21 1.09 
(1.06;1.12) 
1.11x10-10 1.09 
(1.06;1.12) 
1.13x10-10 4.06x10-3 0.00; 
0.04 
14 0.29 0.99
rs6085661 c 
(rs961253) 
20p12.3 
(6,693,128) 
T/C 0.39 1.09 
(1.06;1.11) 
1.63x10-14 1.09 
(1.07;1.11) 
2.95x10-15 3.88x10-8 0.00; 
0.08 
0 0.96 1.00
rs4811050 
(rs1810502) 
20q13.13 
(48,980,670) 
A/G 0.18 1.10 
(1.07;1.13) 
2.43x10-11 1.09 
(1.06;1.12) 
4.07x10-9 4.06x10-3 0.04; 
0.45 
20 0.23 0.99 
rs6091213 
(rs1810502) 
20q13.13 
(49,384,745) 
C/T 0.26 1.08 
(1.05;1.11) 
4.35x10-10 1.08 
(1.05;1.11) 
5.68x10-10 4.76x10-3 0.00; 
0.05 
6 0.39 0.94 
 89 
a Tags to rs1957636 (r2=0.67, D'=1). Previously identified in Tomlinson IP, Nat Genet, 2008 (PMID:18372905) 90 
b Previously identified in Tomlinson IP, Nat Genet, 2008 (PMID:18372905) 91 
c Tags to rs4813802 (r2=0.75,D'=0.93). Previously identified in Tomlinson IP, Nat Genet, 2008 (PMID:18372905) 92 
 93 
RAF, risk allele frequency; OR, odds ratio; CI, confidence interval; BFDP, Bayesian False Discovery Probability; I2, 94 
proportion of the total variation due to heterogeneity; Phet, P-value for heterogeneity. BFDP calculated using prior = 10-5 95 
and maximum relative risk = 1.2. LD calculated based on European populations in the 1000 Genomes Project data. BFDP 96 
calculated using conditional analysis results, with prior = 10-5 and maximum relative risk = 1.2. 97 
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